Braskem S.A. (BAK) FinancialsBAKBraskem S.A.

Braskem S.A. (BAK) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Brazil, accounting for 71.7% of total sales, equivalent to $2.11B. Other significant revenue streams include USA and Europe and Mexico. Understanding this composition is critical for investors evaluating how BAK navigates market cycles within the Commodity Chemicals industry.

Evaluating the bottom line, Braskem S.A. maintains a gross margin of 24.48%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 19.59%, while the net margin is 15.30%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively BAK converts its operational activities into shareholder value.

In the context of the broader market, BAK competes directly with industry leaders such as CBT and HWKN. With a market capitalization of $745.17M, it holds a significant position in the sector. When comparing efficiency, BAK's gross margin of 24.48% stands against CBT's 19.35% and HWKN's 23.44%. Such benchmarking helps identify whether Braskem S.A. is trading at a premium or discount relative to its financial performance.

Braskem's financial performance shows volatility, with a gross margin of 24.48% in Q2 2026, but it has also reported significant net losses, including a net income loss of -$1.9 billion in Q4 2025. The company's total debt stands at $13.04 billion, raising concerns about its financial health.